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Summary The human papillomavirus has emerged over the past decade as the leading candidate to be the
sexually transmitted aetiological factor in cervical cancer. Although it appears that papillomavirus types 16
and 18 are associated with a higher risk of advanced cervical neoplasia, most of the evidence comes from
studies which do not satisfy basic epidemiological requirements, and are therefore difficult to interpret. The
most significant problems are the small sample size, potentially biased selection of study subjects, the
difficulties in cytologically distinguishing precancerous lesions from papilloma infection of the cervix, the
unknown specificity and sensitivity of the various hybridisation methods for determining papillomavirus
infection status, and the statistical analyses and presentation of results. On the basis of the existing studies,
one is forced to conclude that, while experimental data suggest an oncogenic potential for HPV, the
epidemiological evidence implicating it as a cause of cervical neoplasia is still rather limited.
Independently of her age, a woman's risk of cervical cancer
is strongly associated with various measures of sexual
activity, and specifically the number of partners, and age at
first intercourse (Brinton and Fraumeni, 1986). The
independent effect of the number of partners, and the
increased risk for women whose husbands reported multiple
sexual partners (Buckley et al., 1981; Harris et al., 1980;
Reeves et al., 1985; Zunzunegui et al., 1986) strongly
suggests the role of a sexually transmitted infectious agent,
although other factors, such as oral contraceptive use and
smoking may also be important (Harris et al., 1980;
Winkelstein et al., 1984). For over twenty years, much
attention was focused on herpes simplex type 2, but its role
in cervical neoplasia has never been adequately confirmed
(Armstrong et al., 1986) or refuted (Vonka et al., 1984). The
currently favoured hypothesis is that certain types of human
papillomavirus (HPV) play a key aetiological role (Howley,
1986).
Although this hypothesis emerged thirteen years ago (zur
Hausen et al., 1974) and has been supported by experimental
data, it has been difficult to test it epidemiologically because
of the problems in assessing HPV exposure. It has neither
been possible to grow the virus in vitro, nor to develop
a reliable serological test for its antigens. HPV infection
was therefore initially assessed using clinical criteria,
supplemented by colposcopy, cytology and histopathology.
Electron microscopy and immunoperoxidase staining of the
HPV capsid antigen provided more specific means of
detecting the virus in active infections, but it was not until
the cloning of HPV-DNA in bacteria and the application of
DNA hybridisation methods that the large variety of HPV
types (today close to 50) was recognized, and a means of
assessing type-specific infection became available, as reviewed
by McDougall et al., (1986). Types 6 and 11 have since been
associated with benign lesions (condylomas) or low grade
dysplasia while types 16 and 18 have been linked to cervical
cancer (Crawford, 1983; Howley, 1986). HPV types 31, 33
and 35 have been reported in only a few case-series.
Some doubt has recently been cast on the role of the virus
in cervix cancer by reports of high prevalence of HPV 16 and
18 in normal cervical tissue (Cox et al., 1986; Macnab et al.,
1986; Meanwell et al., 1987; Reeves et al., 1987; Schneider et
al., 1987), and the possibility that the apparent association
with cervical neoplasia disappears after age-adjustment
(Meanwell et al., 1987). In the light of the continuing debate
about the importance of HPV infection in the aetiology of
cervical cancer (Editorial, 1987a,b; Mufioz & Bosch, 1987)
and confronted by practical problems in the design of our
own epidemiological study, we decided to critically evaluate
the available epidemiological evidence, which consists of
prevalence surveys of HPV in various population groups,
and some cohort studies of women with cervical HPV
infection or low-grade dysplasia. This paper does not
consider the large body of experimental evidence, which has
been reviewed elsewhere (Pfister, 1987; zur Hausen &
Schneider, 1987).
HPV prevalence surveys
Table I summarizes all published studies in which the
prevalence of infection with HPV types 6, 11, 16 or 18, as
determined by DNA hybridisation in fresh cells or tissue
specimens, is reported for groups of 10 or more women with
cervical neoplasia or normal cervices. Results on HPV31, 33
and 35 are not included in this table as type 31 has been
analyzed only in one of these studies (Lorincz et al., 1986),
and 33 and 35 in no studies. The table gives the number of
subjects tested in each cervical lesion group (invasive
carcinoma, cervical intraepithelial neoplasia, referred to as
CIN, or normal), and the percentage positive for various
types of HPV in each group. In five of these studies, HPV
prevalence rates are given separately for the three degrees of
CIN (Lorincz et al., 1986; McCance et al., 1985; Schneider et
al., 1985; Schneider et al., 1987; Wagner et al., 1984). The
initial impression is that within each study women with
cervical neoplasia have HPV DNA of types 16 and 18
detectable in their cervical cells more frequently than women
with normal cervices, that the prevalence rates increase with
the severity of the lesion, and that there is a considerable
variation in prevalence within each lesion group, although
most of the studies are based on small numbers and different
hybridisation techniques have been used. Types 6 and 11 are
seldom found in cervical cancer but appear to be more
frequent in CIN lesions than in the normal cervix. Although
these studies could technically be viewed as case-control
studies, they were not planned as full epidemiological
investigations, and none of them satisfy the usual criteria of
design and analysis which would ensure the elimination of
bias, confounding and chance in their interpretation.
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Table I Prevalence (%) of type-specific HPV-DNA by lesion group
Invasive
squamous cell carcinoma CIN lesion Normal cervix
Number HPV type Number HPV type Number HPV type
Country of of of
(ref) subjects 16 or 18a 6 or 11 subjects 16 or 18a 6 or 11 subjects 16 or 18a 6 or 11
FRG' 18 61.1 29 13.8
FRG2 13 15.4b 15 O.Ob
FRG3 17 47.1c 6.0 80 32.5 15.0
FRG4 35 54.3c 22.9 36 0.Oc 11.0
FRGs 67 46.0c 28.0 229 2.0c 0.4
FRG/US6 25 48.0c 0.0 144 45.8c 12.5 78 25.6c 14.0
UK7 11 45.5 7 42.9 12 0.0
UK8 13 92.0 0.0 78 62.0 28.0 17 18.0 0.0
UK9 44 66.0 26 34.6
UKI0 27 29.6c 7.4 106d 18. 1.9
UK'" 17 12.0 1ge 10.5
UK' 2 13 38.5
US13 39 56.0c 0.0 26 34.6 3.8 191 0.0 0.5
US14 11 18.2 0.0 12 50.0 38.9
US"s 18 83.3 0.0
Panama'6 20 60.0 12 25.0 17 0.0
Panama' 7 50 70.0c 51 45.0c
Panama'8 120 23.0c




studies in which the histology or cytology of the lesion was specified and DNA
aUnless otherwise noted, figures are for type 16 only; bType 18 only; cTypes 16 and 18 combined; dTwo control
groups were used, one for women with inflammatory cervical lesions, the other of women with normal cervical
cytology; eTwo control groups were used, one from a venereal disease clinic and the other from a family planning
clinic.
'Durst et al., 1983; 2Boshart et al., 1984; 3De Villiers et al., 1986; 4Wagner et al., 1984; 'Schneider et al., 1985;
6Schneider et al., 1987; 7Scholl et al., 1985; 8McCance et al., 1985; 9Meanwell et al., 1987; I'Toon et al., 1986;
''Wickenden et al., 1985; '2Cox et al., 1986; '3Lorincz et al., 1986; '4Fukushima et al., 1985; "Crum
et al., 1986; '6Prakash et al., 1985; 17Reeves et al., 1987; '8Reeves (pers. comm).); '9McCance et al., 1986;
2'Yoshikawa et al., 1985.
Nevertheless, they still contribute the main body of
epidemiological evidence in support of the HPV/cervical
cancer relationship. It is therefore important to understand
their shortcomings in some detail.
Source ofcases and controls
Some of the studies do not include controls or do not
describe the source of case and control material sufficiently
clearly to enable the evaluation of any selection biases
(Boshart et al., 1984; Crum et al., 1986; De Villiers et al.,
1986; Durst et al., 1983; Fukushima et al., 1985; McCance et
al., 1986; Yoshikawa et al., 1985). In some papers which do,
the subjects come from a limited number of clinics or
hospitals, but it is still not clear whether any further
selection has taken place (Cox et al., 1986; Lorincz et al.,
1986; Macnab et al., 1986; Meanwell et al., 1987; Schneider
et al., 1987; Scholl et al., 1985; Wagner et al., 1984;
Wickenden et al., 1985). Information on the source of cases
is important in the choice of the control group. If case and
control HPV DNA prevalence rates are to be used to
estimate the relative risk of HPV infection in causing cervical
neoplasia, the controls must be a representative sample of
the population which gave rise to the cases. For example, if
cases are drawn from a radiotherapy clinic and controls
from a series of women with benign gynaecological disorders
(Meanwell et al., 1987), it is possible that the two series
differ substantially in terms of sexual behaviour, social
class or other factors which influence HPV infection rates.
Lack of information on source population also makes
comparisons ofprevalence between studies very difficult.
Definition ofcases and controls
In studies of HPV in cervical carcinomas, there is little
ambiguity about what constitutes a case. However, in studies
of CIN, the definition of a case is generally based on
cytological and histological criteria, and it can be difficult to
distinguish, on morphological grounds only, CIN from the
subclinical HPV infection sometimes referred to as 'flat and
atypical condylomas' (Koss, 1987). A number of studies have
reported high rates of reclassification from CINI to HPV
infection using recently developed cytological criteria, which
may also reflect a high prevalence of mixed CIN/HPV
lesions (Meisels et al., 1982, 1983). It is thus likely that
published series of CIN samples include a substantial
percentage of what could equally well be classified as HPV
infections, therefore with a high probability of containing
HPV DNA. This would overestimate the HPV prevalence in
precancerous lesions. The same bias might have occurred in
control series, if cytological samples were excluded as
controls when there was any sign of abnormality, whether
characteristic of CIN or HPV infection. In this way,
individuals in whom HPV-DNA was present could actually
have been excluded, artificially lowering the prevalence in the
control series. In a case-control study, a control should be
defined by the absence of the disease which defines the case,
regardless of the presence or absence of the exposure under
study, which in this case is HPV.
Cervical sampling methods
In many comparisons between cervical neoplasia and control
series, biopsy material is used for cancer or CIN cases, while
cytological specimens are analyzed from women with CIN orHUMAN PAPILLOMAVIRUS AND CERVICAL CANCER 3
normal cervices. A biopsy is directed to the lesion of interest,
but it also contains a variable proportion of normal stromal
cells. On the other hand, cytological sampling covers the
whole cervix, but may only obtain relatively few cells from
areas containing HPV DNA. Since no study has been made
comparing results from the two methods carried out on the
same patients, it is not clear what effect this difference has
on the comparison between prevalence estimates (Lorincz et
al., 1986).
DNA hybridisation methods
There are at least three main different groups of techniques
for preparing DNA from exfoliated cells or tissue specimens
before HPV probes are applied for hybridisation. The
Southern blot involves the hybridisation of radiolabelled
cloned HPV DNA to cellular DNA which has been
extracted, cut and separated by gel electrophoresis. This
technique allows the identification of specific HPV DNA
sequences and determination of their integration status in
the cellular DNA. In a variant of this technique called
'reverse hybridisation' it is the cellular DNA which is
radiolabelled, and then hybridised to cloned HPV DNA
separated by electrophoresis. In the dot-blot procedure,
cellular DNA is also extracted but the hybridisation probes
are applied to the unseparated DNA sample. This method
does not permit the assessment of integration, and is less
specific than the Southern blot. For the third group of
techniques, DNA is not extracted; the probes are applied
either to fixed tissue (in situ), or to cells which have been
filtered onto nitrocellulose ('filter in situ'). Although all three
groups of techniques are widely used, they have not been
systematically validated against each other, and in many
reports, it is not entirely clear which variant of which
method is being utilized and what is the specific activity of
the radiolabelled DNA probes. Of particular concern for
epidemiological studies is the possibility that the sensitivity
and specificity of the methods in detecting HPV DNA differs
according to whether the sample is from a carcinoma, CIN
or normal tissue. There have been suggestions that the
methods which involve DNA extraction (Southern blot and
dot-blot) are more sensitive when there is a low copy
number of viral DNA per cell as appears to be the case in
cervical tumours, while the in situ methods are more sensitive
when copy number is high in relatively few cells, as is found
in condylomata or normal cervices (Crum et al., 1986;
Schneider et al., 1987; Wagner et al., 1984).
Statistical analysis of the data
Most of the HPV prevalence surveys simply report the
percent of positive samples by cervical lesion. As we have
mentioned earlier, there is no reason to assume that the
groups are comparable for other basic determinants of
cervical neoplasia and HPV infection risk such as age and
ethnic group, and potential risk factors such as other infectious
agents, smoking and oral contraceptive use. If, for example,
the prevalence of HPV infection is related to age, and a
series of cervical cancer cases differs in age from the control
group, a spurious association between infection and cervical
cancer would be produced. The usual approach to this
problem in epidemiological analyses is to adjust for, or
stratify by, such potentially confounding variables. Only
one study does this, for age (Meanwell et al., 1987), and only
two others even mention the mean age of cases and controls
(McCance et al., 1985; Toon et al., 1986).
Cohort studies
There have been a number of studies published to date in
which HPV infection is assessed in women with some
cervical abnormality, who are then followed up for the
occurrence of advanced CIN lesions. These studies are
certainly based on sounder epidemiological ground than the
prevalence surveys, but they share one major deficiency: they
only involve the follow-up of women with some degree of
cervical abnormality, whether CINI or cytologically detected
HPV infection, and a control group of women with cyto-
logically normal cervices is not followed up in a similar way.
Some of them, however, do use internal controls, comparing
the progression rate in women infected with HPV types
assumed to have low malignant potential (HPV6 or I1) with
those in women infected with types suspected to have high
malignant potential (HPV 16 or 18).
Several studies made an initial classification of HPV
infection based on cytology alone (De Brux et al., 1983;
Meisels & Morin, 1986; Mitchell et al., 1986; Nash et al.,
1987). If the presence of HPV is not initially confirmed by
DNA hybridisation, one might be following up a certain
number of women who already have CIN not associated
with HPV, because of the difficulties in cytologically dis-
tinguishing the two conditions (Koss, 1987; Meisels et al.,
1983). One of the studies used population expected rates of
carcinoma in situ for comparison (Mitchell et al., 1986).
Since women with cervical abnormalities are likely to have
had more subsequent smears than those in the comparison
group which includes a proportion of women who do not
undergo regular screening, the observed excess may be in
part due to underdiagnosis in the latter.
Three studies assess HPV exposure on the basis of type-
specific DNA hybridisation (Campion et al., 1986; Schneider
et al., 1987; Syrjanen et al., 1986). Campion et al. (1986)
carried out DNA hybridisation on cytological samples from
women with CINI, both at initial diagnosis and during
follow-up, and there was an impressive difference in the
progression rate according to the HPV type. The frequency
of progression to CINIII after 2 years was 56% for the 39
women in whom type 16 had been detected, and only 20%
for the 46 women in whom type 6 had been found. This
study seems to provide strong evidence for the role of HPV
type 16 in progression. However, the women followed in this
study were a selected group of women who were not only
young (all were under 30, with mean age 22.4) but had had
three consecutive smears positive for CINI. It would be
important to reproduce these findings in a more represent-
ative group, including women who were cytologically
normal at the start of follow-up. In addition, it is not clear
whether the initial DNA hybridisation results are used to
classify each woman throughout the study.
Syrjanen et al. (1986) are conducting another study in
which 418 women with cytologically-detected and, in a
smaller percentage, DNA-typed HPV infection are being
followed up by regular cervical biopsy or cytology. The
progression rate to 'advanced CIN' is higher among the
women who were infected with types 16 or 18 than among
those in whom types 6 or 11 were detected. The number of
cases is still small, and the differences are not clearly
significant. Furthermore, the repeat biopsies being carried
out as lesions progress could alter the natural history of the
lesions, complicating the interpretation of the results.
The third study is again of women with cytological
abnormalities (Schneider et al., 1987). A group of women
with a cytological diagnosis of CIN or condyloma were
followed up for progression to higher grade CIN or cancer.
Five out of 24 women in whom only HPV 16/18 was
detected progressed to CINIII, as compared with none of 12
women positive for HPV6/11 alone.
Discussion
Whereas there is an impressive body of experimental
evidence suggesting an oncogenic potential for certain
HPV types, no epidemiological study has convincingly
demonstrated that HPV causes cervical cancer. The ideal4 N. MUNOZ el al.
study of the relationship between HPV and cervical cancer
would be one in which a large unselected group ofwomen was
examined for HPV infection and other potential risk factors,
and then followed up for the occurrence of cervical cancer.
Apart from the expense of such a study, and the length of
time which would need to elapse for sufficient cases to
occur, this design would not be feasible for ethical reasons:
Cervical cancer should not be permitted to occur in a group
of women who are undergoing systematic follow-up. This
leaves three options for epidemiological designs:
(i) Cohort studies identical to the ideal study referred to
above, except that CIN III is used as a surrogate
endpoint.
(ii) Case-control studies comparing the frequency of
papilloma infection between samples from women
with neoplastic lesions of the cervix and women
with normal cervices.
(iii) A posteriori linkage of invasive cancer or CIN III
cases and appropriate controls to stored cervical
cytological samples, taken before the diagnosis of
cervical neoplasia.
The disadvantage of design (i) is that even if women with
cytologically normal cervices are followed up, any
association detected will be with carcinoma in situ, and the
role of HPV in the progression to invasive cancer will not be
established. Design (ii) suffers from the temporal ambiguity
which arises in case control studies: a spurious association
may be observed if HPV DNA is more readily detected in
tumours than normal tissue, or if the risk of infection is
increased in tumour tissue. Design (iii) relies on the ability to
store a large number of samples, and retrieve for HPV
analysis those from women who develop cervical neoplasia,
and from suitably chosen controls who do not.
Laboratory scientists have made great advances during the
last 5 years in providing the appropriate tools to assess type-
speciic 1 infection with HPV. However, these methods are not
yet properly validated to the point where they can be applied
in large-scale epidemiological studies. For the moment, one
must conclude that the epidemiological evidence linking
HPV infection to cervical cancer remains limited, both by
the design of existing studies, and by unanswered questions
concerning the most appropriate means of assessing HPV
infection.
Note added in proof
After submission of this paper, a report was published which
describes the largest series of cervical cytological samples so
far analyzed for the presence of HPV DNA. Although the
prevalence is clearly higher in women with cervical lesions
than in those without, the study suggests that the filter in
situ hybridisation test is much less sensitive than the
Southern blot. The study also reports a decrease with age of
the prevalence of HPV DNA positivity for types 6/11 and
16/18 combined in women with a normal cytology; there
was, however, no change with age of this prevalence in
women with cytological diagnosis of CIN or invasive cancer
(de Villiers et al., 1987).
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